索引于
  • 学术期刊数据库
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 中国知网(CNKI)
  • 乌尔里希的期刊目录
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Induction of Tolerance to Clopidogrel in a Patient with Ischemic Cardiopathy

David El-Qutob, Gemma Mencia and Maria Jose Bosch

Patients with acute coronary syndrome (ACS) that are admitted in the emergency room are treated with AAS and a loading dose of clopidogrel (300-600 mg) unless contraindicated. A 47 year old male was admitted in the cardiology ward with the diagnosis of ACS. He was revascularized with two drug eluting stents. A loading dose of 300 mg of clopidogrel was used and a 12 months period with dual antiplatelet therapy was recommended (AAS 100 mg plus clopidogrel 75 mg per day). After seven days taking clopidogrel and AAS, the patient presented non-immediate erythematous, pruritic, maculopapular rash. He tolerated AAS after skin reaction. The patient was referred to our department by the cardiology service to perform an induction of tolerance to clopidogrel. There are several, outpatient and inpatient, protocols of desensitization to clopidogrel usually in one day, all of them with good results. To allow hypersensitivity symptoms to resolve before performing desensitization, these protocols require a drug washout period during which time patients are at risk for stent thrombosis while clopidogrel is withheld. We present a method for induction tolerance in a patient with probably hypersensitivity to clopidogrel who has discontinued the medication. The induction of tolerance to clopidogrel has allowed the patient to continue taking this medication necessary for his health in a quickly and safely way.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证